A change in the trend in dosulepin usage following the introduction of a prescribing indicator but not after two national safety warnings.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Subject Terms:
      WALES; ENGLAND
    • Abstract:
      What is known and objective: The tricyclic antidepressant dosulepin has been associated with an increased risk of toxicity in overdose compared with other antidepressants. In the UK, the MHRA and NICE have issued advice on the prescribing of dosulepin, and a National Prescribing Indicator (NPI) to monitor usage was introduced in Wales in 2011. The aim of this study was to assess whether trends in dosulepin usage in Wales and NE England changed following the two pieces of safety guidance and the introduction of the National Prescribing Indicator in Wales. Methods: Primary care dosulepin usage in the 12 months prior to and following MHRA safety advice (in 2007), NICE guideline CG90 (in 2009) and the introduction of the NPI (in 2011) was obtained. Usage was measured using defined daily doses (DDDs) per 1000 prescribing units (PUs). The trends in the 12 months prior to and following the introduction of prescribing advice and the NPI were compared using an autoregressive integrated moving average (ARIMA) model. Results and discussion: In Wales, the trend in dosulepin usage did not change significantly prior to and following the MHRA advice: -0.18 and -0.43 DDDs/1000PUs per month, respectively (P = 0.07), or prior to and following NICE CG90: -0.30 and -0.49 DDDs/1000PUs per month, respectively (P = 0.35). In the 12 months prior to and following the introduction of the NPI, the trend was -0.45 and -0.98 DDDs/1000PUs per month, respectively (P = 0.001). In NE England, the trend did not alter significantly following the NICE advice or the introduction of the NPI in Wales. What is new and conclusion: The trend in dosulepin usage in Wales altered significantly following the introduction of the NPI, but not after the other prescribing advice. This association, coupled with the absence of a significant change in NE England over the same period, provided some evidence of the effectiveness of the NPI in prompting a change in prescribing behaviour in Wales. [ABSTRACT FROM AUTHOR]
    • Abstract:
      Copyright of Journal of Clinical Pharmacy & Therapeutics is the property of Wiley-Blackwell and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)